Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSA003 in Homozygous Familial Hypercholesterolaemia (HoFH)
NCT06712771Phase 3Active, not recruiting
- Sponsor
- Visirna Therapeutics
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in homozygous familial hypercholesterolemia (HoFH) comparing VSA003 with Placebo (2 arms). Primary endpoint: Percent change from baseline in serum LDL-C at 6 months. Started Nov 2024; status: active, not recruiting.
02
Drugs
zodasiran
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT06712771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712771.